Decoding Big Pharmas R&D Strategy in Oncology

Questions: Discounts, Updates etc.

Pages: 243

Price (Single): $3450

Price (Departmental):

Price (Company):

Publication Date: 2007-09-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Introduction

This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on an analysis of some of the major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Novartis and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Each of these oncology field leaders are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.

This report focuses on Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five included big pharma companies. The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.

Decoding Big Pharma’s R&D Strategy in Oncology in numbers:

 

Other users found this report page using the following search terms: oncology

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.